Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
SIB Swiss Institute of Bioinformatics | RCV000721926 | SCV001146848 | likely pathogenic | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2 | 2019-10-17 | criteria provided, single submitter | curation | This variant is interpreted as Likely pathogenic for Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2 , autosomal recessive. The following ACMG Tag(s) were applied: PM2, PP3, PM3, PS3. |
Prevention |
RCV003398447 | SCV004111781 | pathogenic | TREM2-related disorder | 2022-12-14 | criteria provided, single submitter | clinical testing | The TREM2 c.377T>G variant is predicted to result in the amino acid substitution p.Val126Gly. This variant has been reported in individuals with Nasu-Hakola disease, also referred to as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Klünemann et al 2005. PubMed ID: 15883308; Lynch DS et al 2017. PubMed ID: 28334938). Functional studies showed the p.Val126Gly change disrupts TREM2 trafficking to the cell membrane and impairs function (Sirkis DW et al 2017. PubMed ID: 28768830; Kober DL et al 2016. PubMed ID: 27995897). This variant is reported in 0.0098% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/6-41129015-A-C).This variant is interpreted as pathogenic. |
OMIM | RCV000721926 | SCV000025710 | pathogenic | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2 | 2005-05-10 | no assertion criteria provided | literature only | |
Gene |
RCV000005528 | SCV000223800 | not provided | Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 | no assertion provided | literature only |